New Immune-Boosting combo enters fight against tough cancers
NCT ID NCT05661955
Summary
This study is testing whether a new immunotherapy drug (BGB-A445) works better when combined with an existing one (tislelizumab) to treat advanced bladder, kidney, or skin cancers. It aims to see if the combination can shrink tumors and is safe for patients. The trial is for people whose cancer has spread or returned after trying at least one other treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Jining No1 Peoples Hospital West Branch
Jining, Shandong, 272000, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Hospital and Clinical Medical School, Lanzhou University
Lanzhou, Gansu, 730030, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
The Tumor Hospital Affiliated to Guangxi Medical University
Nanning, Guangxi, 530021, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.